Gilead Sciences Company Profile

What Do the Latest SEC Filings Show for Gilead Sciences?

These are figures Gilead Sciences reported in its own SEC filings, read from the SEC's XBRL data, so the page has a fixed starting point before any of the research questions below. They describe reported history and are not a forecast.

Source: SEC EDGAR: GILEAD SCIENCES, INC. Form 10-K filed February 24, 2026.

Company snapshot

What Gilead Sciences does

Gilead develops and commercializes medicines concentrated in HIV, viral hepatitis, oncology and other serious diseases. Long-lived HIV franchises generate substantial cash flow, while pipeline productivity and oncology diversification are central to future growth.

The business is best understood through HIV; Liver Diseases; Oncology; Other therapeutics. Those areas are not interchangeable with products. For Gilead Sciences, they are the economic buckets an investor should use when connecting demand, pricing, cost and capital requirements.

Economically significant offerings include Biktarvy and other HIV therapies, Descovy/PrEP products, Trodelvy, CAR-T therapies, liver-disease medicines. The useful question is not which product is best known. For Gilead Sciences, the more useful question is which product creates customer acquisition, which deepens retention, which carries the best incremental economics, and which requires the most reinvestment.

Patients are the end beneficiaries; economic purchasers include health systems, pharmacies, insurers, governments and distributors. For Gilead Sciences, this customer mix matters because purchasing cycles, bargaining power and switching costs differ. For Gilead Sciences, the analyst should distinguish the contractual customer from the end user and identify when a distributor, platform or regulator sits between them.

How Gilead Sciences makes money

Gilead Sciences operates primarily as a research-driven biopharmaceutical company. Biopharma economics combine high gross margins on successful products with long, risky R&D cycles. Gilead's established antiviral cash flows can fund dividends, acquisitions and pipeline investment, but product concentration and patent cliffs matter.

Revenue is driven by:

• HIV prescription volume and share
• new indications and launches
• oncology uptake
• pricing and payer access
• patent lifecycle
• R&D productivity

The analytical center of gravity is the research-driven biopharmaceutical company model. For Gilead Sciences, the investor should identify which parts create repeat economics and which depend on cyclical demand, capital investment or external suppliers. For Gilead Sciences, this distinction explains why two periods with similar reported revenue growth can carry very different implications for long-run value creation.

Revenue engine

For Gilead Sciences, a durable revenue map should connect demand, price, volume, retention and capacity. For Gilead Sciences, the leading operating indicators are most closely related to HIV prescription volume and share, new indications and launches, oncology uptake, pricing and payer access, patent lifecycle. For Gilead Sciences, a change in one driver should not automatically be treated as structural. At Gilead Sciences, the change may reflect seasonality, mix, a product transition, customer inventory, macro conditions or a competitive response.

For Gilead Sciences, the investor should also ask whether growth is volume-led, price-led, mix-led or acquisition-led. Those paths have different durability and cash requirements. Gilead Sciences can grow reported revenue while weakening the economics of each incremental dollar if incentives, capacity additions or customer acquisition costs rise too quickly.

Business segments and economically important products

The default research map uses:

• HIV
• Liver Diseases
• Oncology
• Other therapeutics

Important products and services include:

• Biktarvy and other HIV therapies
• Descovy/PrEP products
• Trodelvy
• CAR-T therapies
• liver-disease medicines

When formal reporting segments change, historical comparability should be preserved instead of silently rewriting old data. For Gilead Sciences, a strategically important activity may not be separately reported, while a reported segment can contain businesses with very different margins. For Gilead Sciences, Swoopr's editorial layer should explain that difference rather than merely reproduce filing labels.

For each Gilead Sciences segment, the reader should be able to answer four questions: who buys, what unit creates revenue, which costs scale with activity, and what could make the segment structurally more or less profitable. That is more useful than a segment list alone.

Customers, channels and demand formation

Patients are the end beneficiaries; economic purchasers include health systems, pharmacies, insurers, governments and distributors.

For Gilead Sciences, customer analysis should answer who pays, who influences the purchase, who controls distribution and whether the company depends on a small number of counterparties. For Gilead Sciences, it should also identify purchasing cadence: daily, transactional, annual contract, multi-year deployment, prescription cycle, loan term or capital-project cycle.

For Gilead Sciences, demand formation is most usefully monitored through HIV market share, oncology launch trajectory, clinical readouts, regulatory decisions. If Gilead Sciences's indicators weaken before reported revenue does, the lag can be informative. If Gilead Sciences's indicators improve without revenue following, the analyst should look for capacity, pricing or accounting timing explanations.

Geography and operating exposure

Gilead Sciences is headquartered in Foster City, California, but economic exposure extends beyond headquarters. For Gilead Sciences, geographic analysis should distinguish customer location, revenue recognition, manufacturing or infrastructure location, legal domicile and currency exposure.

The country field in Swoopr's registry is United States. That is not a shortcut for risk. For Gilead Sciences, the relevant map is the chain of customers, suppliers, regulators, assets and cash flows. For international issuer or ADR analysis involving Gilead Sciences, the security wrapper and reporting regime must also be explained separately from the underlying operating geography.

For Gilead Sciences, geography becomes especially important when one country is simultaneously a major customer market, manufacturing base and regulatory jurisdiction. In Gilead Sciences's case, a single geopolitical event can affect both demand and supply.

Business model and company economics

Biopharma economics combine high gross margins on successful products with long, risky R&D cycles. Gilead's established antiviral cash flows can fund dividends, acquisitions and pipeline investment, but product concentration and patent cliffs matter.

The analytical center of gravity is the research-driven biopharmaceutical company model. For Gilead Sciences, the investor should identify which parts create repeat economics and which depend on cyclical demand, capital investment or external suppliers.

For Gilead Sciences, the core economic questions are:

• For Gilead Sciences, what is the scarce resource in the model?
• For Gilead Sciences, does scale lower unit cost, deepen a network, improve data, increase purchasing leverage or simply add complexity?
• For Gilead Sciences, is growth funded internally or does it routinely require external capital?
• How quickly can price change relative to cost?
• How much revenue is recurring, repeat or contractually visible?
• What portion of margin is structurally defensible?
• Which reinvestment is maintenance and which is expansion?

For Gilead Sciences, a useful answer should be grounded in HIV product sales, Biktarvy growth, oncology sales, R&D expense, pipeline milestones rather than a generic claim that the company has a moat. For Gilead Sciences, competitive advantage is valuable only when it protects customer relevance, economics or reinvestment returns.

How to read Gilead Sciences's financial statements

Focus on product sales by franchise, gross-to-net adjustments, R&D, acquired in-process R&D, collaboration expenses, intangible amortization and cash deployment. One-time acquisition charges can obscure underlying operating trends.

For Gilead Sciences, life-sciences and medical-technology accounting must be read alongside product lifecycle and development economics. For Gilead Sciences, r&D is expensed before a successful product may generate revenue, acquisitions can create large intangibles, and regulatory milestones can change expected cash flows abruptly. For Gilead Sciences, recurring commercial performance should be separated from acquired R&D, milestone, restructuring and impairment charges.

Income statement

For Gilead Sciences, start by identifying the revenue lines corresponding to real operating drivers. Then separate gross-margin or spread economics from operating-expense choices. For Gilead Sciences, the most decision-useful measures include HIV product sales, Biktarvy growth, oncology sales, R&D expense, pipeline milestones. For Gilead Sciences, management-adjusted measures can be useful when they reconcile to the statutory statements and do not make recurring economic costs disappear.

Balance sheet

For Gilead Sciences, the balance sheet shows what the business must own, finance or reserve against to produce the income statement. For Gilead Sciences, examine cash, debt, inventory or earning assets as appropriate, plus acquisition intangibles, lease obligations, deferred revenue, supplier commitments and equity issuance. For Gilead Sciences, the right question is not simply whether debt is high, but whether the financing structure fits the durability and cyclicality of cash flows.

Cash flow statement

For Gilead Sciences, cash flow connects accounting earnings to economic reality. For Gilead Sciences, working-capital movements, stock compensation, acquisition payments and capital expenditures can make cash flow temporarily look stronger or weaker than normalized economics. Gilead uses cash for R&D, acquisitions/licensing, dividends and repurchases while maintaining manufacturing and commercial capabilities.

Capital intensity and free cash flow

For Gilead Sciences, capital intensity should be evaluated relative to the model. For Gilead Sciences, software can become infrastructure-heavy; retail can create favorable working capital; energy can produce high cash while depleting reserves; a REIT can require large development spending. For Gilead Sciences, connect capital spending to next-generation HIV, PrEP expansion, oncology indications and ask what return the incremental investment is expected to earn.

Metrics that matter most

For Gilead Sciences, the following metrics are more useful than a generic quote-page dashboard because they connect directly to the operating model.

For Gilead Sciences, a metric belongs in the monitoring set only if it can change a decision. For Gilead Sciences, if management stops disclosing it, When a metric is discontinued, no estimated value should replace it without a documented, reproducible methodology and a reliable data source.

Trends matter more than isolated datapoints. For Gilead Sciences, the reader should compare a KPI with its related revenue line, margin, cash cost and management explanation. For Gilead Sciences, a metric that grows while cash economics deteriorate may be measuring activity rather than value creation.

Competitive position

Relevant competitors or substitutes include ViiV Healthcare/GSK, Merck, Bristol Myers Squibb, Roche, other oncology and antiviral developers.

For Gilead Sciences, competitive analysis should be conducted at the customer-job level rather than assuming every peer competes across the entire company. For Gilead Sciences, scale may matter because it lowers unit cost, funds R&D or increases network density. Brand may reduce acquisition cost or support price. Switching costs may be contractual, operational, behavioral or regulatory. For Gilead Sciences, what matters is the mechanism and what evidence would show it weakening.

For Gilead Sciences, a competitive advantage can also become a vulnerability if it creates concentration. For Gilead Sciences, a dominant channel can raise regulatory scrutiny; a strategic customer can gain bargaining power; a tightly integrated supply chain can be harder to reroute. The analysis therefore needs both the advantage and its failure mode.

Supply chain and dependencies

Gilead relies on internal and external manufacturing, specialized biologics/cell-therapy processes, active ingredients, contract manufacturers and regulated distribution networks.

For Gilead Sciences, supply-chain analysis should identify not only the direct vendor but the constrained tier beneath it. For Gilead Sciences, a company may have many nominal suppliers yet depend on one foundry node, one regulatory approval, one grid interconnection, one aircraft family, one payments rail or one logistics route.

For Gilead Sciences, the practical monitoring questions are capacity, lead time, price, substitutability and geography. For Gilead Sciences, if a dependency cannot be substituted quickly, its economic importance can exceed the dollar amount shown in procurement disclosures.

Economic sensitivity

Drug pricing policy, reimbursement, public-health budgets and interest rates affect economics, but clinical data and regulatory outcomes usually matter more than broad GDP cycles.

For Gilead Sciences, macro sensitivity should not become a laundry list. The goal is to identify the transmission mechanism. For Gilead Sciences, a higher interest rate can change consumer financing, bank deposit pricing, property cap rates or corporate capex; those are different mechanisms. For Gilead Sciences, the variables above should be connected to operating metrics before they are connected to a stock-price narrative.

A second question is timing. For Gilead Sciences, some businesses reprice daily; others operate under annual contracts, regulated tariffs, hedges or long project cycles. For Gilead Sciences, the same macro shock can therefore reach reported earnings at very different speeds.

Company history and strategic timeline

For Gilead Sciences, a useful company history explains how today's economics were created.

The chronology is intentionally selective. For Gilead Sciences, exact dates and transaction values should be added only after verification in primary filings, investor-relations materials or reliable historical sources. The purpose of the timeline is causal context, not trivia.

Capital allocation

Gilead uses cash for R&D, acquisitions/licensing, dividends and repurchases while maintaining manufacturing and commercial capabilities.

For Gilead Sciences, capital allocation should be evaluated across organic reinvestment, acquisitions, debt, dividends, repurchases and equity issuance. The correct benchmark is opportunity cost. For Gilead Sciences, a buyback can create value at one price and destroy it at another; an acquisition can accelerate strategy or hide slowing organic growth.

For Gilead Sciences, capital decisions should be reviewed alongside gross margin, free cash flow, patent/exclusivity dates. For Gilead Sciences, the most important question is whether management is allocating the next dollar to the highest credible risk-adjusted return while preserving enough balance-sheet resilience for a downturn.

Growth drivers

Potential operating growth mechanisms include:

• next-generation HIV
• PrEP expansion
• oncology indications
• cell therapy
• business development

For Gilead Sciences, these are mechanisms, not forecasts. For Gilead Sciences, each should be paired with an observable sign of progress and failure. For Gilead Sciences, a useful growth narrative is falsifiable: it specifies what must become larger, more efficient or more valuable and what data would demonstrate that change.

Growth quality also matters. For Gilead Sciences, organic volume, price, cross-sell, acquisitions and capacity expansion can all create the same headline growth rate while having different incremental returns. Keeping that distinction in view is part of reading the company's results.

Risk framework

The most relevant risk areas include:

• clinical failure
• patent expiration
• pricing pressure
• product concentration
• acquisition returns
• manufacturing/regulatory issues

The assessment is intentionally qualitative. For Gilead Sciences, assigning a numerical probability without a documented methodology would create false precision. For Gilead Sciences, the goal is to identify the causal path from risk to an observable operating signal.

Risks should also be tested for interaction. For Gilead Sciences, for example, a demand slowdown may be manageable with a strong balance sheet but more severe when it coincides with refinancing pressure, inventory buildup or a product transition.

Bull, base and bear operating framework

Bull operating case

A favorable operating case would require several growth mechanisms to work at the same time, with HIV market share, oncology launch trajectory, clinical readouts supporting the thesis. For Gilead Sciences, margins or cash conversion would also need to remain resilient enough that growth creates economic value rather than merely more revenue.

Base operating case

A base case assumes normal execution: the core franchise remains competitive, necessary reinvestment is funded, and growth comes from a mix of existing demand and the more mature opportunities in next-generation HIV, PrEP expansion, oncology indications. It does not require perfect macro conditions or flawless execution.

Bear operating case

A bearish operating case would emerge if one or more of clinical failure, patent expiration, pricing pressure, product concentration materially worsened and management could not offset the deterioration through pricing, cost action, innovation or capital allocation. For Gilead Sciences, the useful question is which operating metric would confirm deterioration before the narrative becomes consensus.

What could prove an investment thesis wrong?

For Gilead Sciences, a positive thesis should be reconsidered if evidence shows persistent deterioration in the core drivers rather than one noisy quarter.

• A sustained adverse trend in HIV product sales that cannot be explained by a temporary cycle.
• A sustained adverse trend in Biktarvy growth that cannot be explained by a temporary cycle.
• A sustained adverse trend in oncology sales that cannot be explained by a temporary cycle.
• A sustained adverse trend in R&D expense that cannot be explained by a temporary cycle.

• A structural loss of customer relevance or distribution.
• For Gilead Sciences, capital requirements rising materially faster than the cash returns they are intended to create.
• Competitive responses that permanently reduce pricing power or unit economics.
• For Gilead Sciences, regulatory or technological change that alters the model rather than merely adding expense.

What investors commonly misunderstand about Gilead Sciences

• a mature HIV franchise means no growth opportunity
• all biotech R&D spending has comparable odds
• revenue declines always imply franchise deterioration rather than cure dynamics
• acquisitions diversify risk automatically

Misconceptions matter because they cause investors to use the wrong comparison set or metric. For Gilead Sciences, the objective is not to make a contrarian claim for its own sake; it is to make the economic unit of analysis explicit.

What to monitor

A practical monitoring checklist is:

• HIV market share
• oncology launch trajectory
• clinical readouts
• regulatory decisions
• R&D productivity
• patent timelines

The checklist should change when the company changes reporting structure, enters a new business or experiences a material regulatory or capital-structure event. For Gilead Sciences, monitoring is useful only when each item is tied to a thesis, not when it becomes a collection of quarterly trivia.

Questions investors should ask

• Which of Gilead Sciences's revenue drivers is currently doing the most work?
• Is Gilead Sciences's pricing power strengthening, stable, or weakening?
• For Gilead Sciences, are the economics of the fastest-growing activity better or worse than the legacy business?
• For Gilead Sciences, what does current capital spending imply about management's view of future demand?
• Which customer or supplier concentration deserves the most attention?
• For Gilead Sciences, are margins moving because of durable mix changes or temporary cycle effects?
• For Gilead Sciences, what would have to happen for the most optimistic operating assumptions to fail?
• For Gilead Sciences, does growth require more working capital, fixed assets, or external financing than before?
• Which competitor could most plausibly change industry pricing or customer behavior?
• For Gilead Sciences, what evidence would show that customer switching costs are increasing or decreasing?
• For Gilead Sciences, how much of current cash flow is repeatable through a weaker environment?
• For Gilead Sciences, which regulatory change could alter the business model rather than merely add compliance cost?
• Are acquisitions, buybacks, dividends and organic reinvestment being balanced rationally?
• For Gilead Sciences, what metric should be watched before revenue to detect a change in the business?
• Is management reporting enough operating data to test the thesis independently?

Key takeaways

• Gilead Sciences is best analyzed as a research-driven biopharmaceutical company, not as a ticker or quote.
• Primary drivers include HIV prescription volume and share, new indications and launches, oncology uptake, pricing and payer access.
• The KPI set should begin with HIV product sales, Biktarvy growth, oncology sales, R&D expense, pipeline milestones.
• The competitive set includes ViiV Healthcare/GSK, Merck, Bristol Myers Squibb, Roche.
• Major risks include clinical failure, patent expiration, pricing pressure, product concentration.
• For Gilead Sciences, capital allocation is part of business quality, not a separate footnote.
• For Gilead Sciences, index membership is a security-level fact and must be refreshed from official Nasdaq data.
• For Gilead Sciences, the page is designed to remain useful even if the reader never buys the security.

Frequently asked questions

References

• Gilead Investor Relations
• Gilead SEC filings
• Nasdaq Composite Index overview
• Nasdaq Composite Index Methodology

Source-use note

Index membership and methodology are best checked against Nasdaq directly, because the Composite is reconstituted daily. For Gilead Sciences, company-specific financial claims should be refreshed from the latest annual report, quarterly report, earnings release and investor presentation. For Gilead Sciences, fast-changing valuation statistics are deliberately kept out of evergreen prose unless they are served from a dated data layer.

Educational disclaimer

This dossier is for educational and research purposes. For Gilead Sciences, it does not provide individualized investment advice, a recommendation, a price target or a forecast of investment returns.